MDM2和MDMX在癌症中的作用。
The Roles of MDM2 and MDMX in Cancer.
作者信息
Karni-Schmidt Orit, Lokshin Maria, Prives Carol
机构信息
Department of Biological Sciences, Columbia University, New York, NY 10027; email:
出版信息
Annu Rev Pathol. 2016 May 23;11:617-44. doi: 10.1146/annurev-pathol-012414-040349. Epub 2016 Mar 17.
Abstract
For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been shown to exert oncogenic activity. These two proteins are best understood as negative regulators of the p53 tumor suppressor, although they may have additional p53-independent roles. Understanding the dysregulation of MDM2 and MDMX in human cancers and how they function either together or separately in tumorigenesis may improve methods of diagnosis and for assessing prognosis. Targeting the proteins themselves, or their regulators, may be a promising therapeutic approach to treating some forms of cancer.
摘要
25年多来，MDM2及其同系物MDMX（也称为MDM4）已被证明具有致癌活性。尽管这两种蛋白可能具有其他不依赖于p53的作用，但它们最被理解为p53肿瘤抑制因子的负调节因子。了解MDM2和MDMX在人类癌症中的失调情况，以及它们在肿瘤发生过程中如何共同或分别发挥作用，可能会改善诊断方法和评估预后的方法。靶向这些蛋白本身或其调节因子，可能是治疗某些癌症的一种有前景的治疗方法。
相似文献
1
The Roles of MDM2 and MDMX in Cancer.MDM2和MDMX在癌症中的作用。
Annu Rev Pathol. 2016 May 23;11:617-44. doi: 10.1146/annurev-pathol-012414-040349. Epub 2016 Mar 17.
2
MDM2 and MDM4: p53 regulators as targets in anticancer therapy.MDM2与MDM4：作为抗癌治疗靶点的p53调节因子
Int J Biochem Cell Biol. 2007;39(7-8):1476-82. doi: 10.1016/j.biocel.2007.03.022. Epub 2007 Apr 8.
3
Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.升高的MDM2通过促进MDMX降解增强p53-MDM2结合抑制剂的凋亡活性。
Cell Cycle. 2008 Jun 1;7(11):1604-12. doi: 10.4161/cc.7.11.5929. Epub 2008 Mar 17.
4
Mdmx and Mdm2: brothers in arms?Mdmx和Mdm2：战友？
Cell Cycle. 2004 Jul;3(7):900-4. Epub 2004 Jul 2.
5
Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.MDMX（MDM4）和 MDM2 在乳腺癌增殖和循环肿瘤细胞中的上下文相关作用。
Breast Cancer Res. 2019 Jan 14;21(1):5. doi: 10.1186/s13058-018-1094-8.
6
Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.Mdmx通过改变Mdm2泛素连接酶的底物偏好性来增强p53的泛素化。
FEBS Lett. 2009 Sep 3;583(17):2710-4. doi: 10.1016/j.febslet.2009.07.021. Epub 2009 Jul 18.
7
Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.苯并咪唑类药物下调 Mdm2 和 MdmX 并激活 MdmX 过表达肿瘤细胞中的 p53。
Molecules. 2019 Jun 7;24(11):2152. doi: 10.3390/molecules24112152.
8
Mdmx promotes genomic instability independent of p53 and Mdm2.Mdmx促进基因组不稳定，且不依赖于p53和Mdm2。
Oncogene. 2015 Feb 12;34(7):846-56. doi: 10.1038/onc.2014.27. Epub 2014 Mar 10.
9
MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.MDMX（MDM4），一种用于p53再激活疗法及其他领域的有前景的靶点。
Cold Spring Harb Perspect Med. 2016 Jul 1;6(7):a026237. doi: 10.1101/cshperspect.a026237.
10
Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE.人表皮生长因子受体4（Her4）通过靶向MDMX-MDM2蛋白复合物抑制p53蛋白：一种新型MDMX丝氨酸314磷酸位点的意义
J Biol Chem. 2016 Dec 9;291(50):25937-25949. doi: 10.1074/jbc.M116.752303. Epub 2016 Oct 24.
引用本文的文献
1
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation.MDM2在蛋白降解靶向嵌合体（PROTACs）中的双重功能拓展了靶向蛋白降解的视野。
Biomark Res. 2025 Aug 27;13(1):111. doi: 10.1186/s40364-025-00826-7.
2
Mechanisms of Actinidia chinensis Planch roots in the treatment of breast cancer based on network pharmacology and molecular docking.基于网络药理学和分子对接的中华猕猴桃根治疗乳腺癌的机制
Medicine (Baltimore). 2025 Aug 1;104(31):e43560. doi: 10.1097/MD.0000000000043560.
3
Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.口服酪蛋白激酶1α和细胞周期蛋白依赖性激酶7/9抑制剂BTX A51用于晚期骨髓增生异常综合征和急性髓系白血病的I期首次人体剂量递增研究。
J Hematol Oncol. 2025 Jul 15;18(1):73. doi: 10.1186/s13045-025-01724-z.
4
Cytotoxic and proapoptotic effects of alizarin in mice with Ehrlich solid tumor: novel insights into ERα-mediated MDM2/p-Rb/E2F1 signaling pathway.茜草素对艾氏实体瘤小鼠的细胞毒性和促凋亡作用：对雌激素受体α介导的MDM2/p-视网膜母细胞瘤蛋白/E2F1信号通路的新见解
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 28. doi: 10.1007/s00210-025-04196-7.
5
Analysis of p53-Independent Functions of the Mdm2-MdmX Complex Using Data-Independent Acquisition-Based Profiling.使用基于数据非依赖采集的分析方法对Mdm2-MdmX复合物的p53非依赖性功能进行分析。
Proteomes. 2025 May 22;13(2):18. doi: 10.3390/proteomes13020018.
6
Methylation aberrations and genomic instability synergistically drive the evolution of intrahepatic cholangiocarcinoma.甲基化异常与基因组不稳定性协同驱动肝内胆管癌的进展。
Epigenomics. 2025 Jul;17(10):661-674. doi: 10.1080/17501911.2025.2518919. Epub 2025 Jun 17.
7
Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.通过蛋白酶靶向嵌合体（PROTAC）靶向Mdm2在p53野生型、p53突变型和阿贝西利耐药的雌激素受体阳性细胞系中有效，且优于Mdm2抑制作用。
BMC Cancer. 2025 Jun 1;25(1):978. doi: 10.1186/s12885-025-14361-z.
8
Mechanistic Role of the Mdm2/MdmX Lid Domain in Regulating Their Interactions with p53.Mdm2/MdmX 盖子结构域在调节它们与 p53 相互作用中的机制作用。
Biomolecules. 2025 Apr 30;15(5):642. doi: 10.3390/biom15050642.
9
A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells.一种通过p53信号通路的高选择性且口服生物可利用的酪蛋白激酶1α降解剂靶向B细胞淋巴瘤细胞。
Leukemia. 2025 May 27. doi: 10.1038/s41375-025-02647-x.
10
Epstein-Barr virus nuclear antigen 1 (EBNA1) increases the expression levels of MDM2 and MDM4 genes in HeLa cells: a review on MDM2 and MDM4 roles in cancer.爱泼斯坦-巴尔病毒核抗原1（EBNA1）提高HeLa细胞中MDM2和MDM4基因的表达水平：MDM2和MDM4在癌症中作用的综述
BMC Res Notes. 2025 May 17;18(1):221. doi: 10.1186/s13104-025-07275-3.
本文引用的文献
1
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.MDM2是恶性胸膜间皮瘤铂类培美曲塞治疗的重要预后和预测因素，而P14/ARF（由CDKN2A编码）的失调似乎导致了MDM2驱动的P53失活。
Br J Cancer. 2015 Mar 3;112(5):883-90. doi: 10.1038/bjc.2015.27. Epub 2015 Feb 10.
2
The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.MDM2 抑制剂 AMG 232 具有强大的抗肿瘤疗效，并增强了 p53 诱导细胞毒性药物的活性。
Mol Cancer Ther. 2015 Mar;14(3):649-58. doi: 10.1158/1535-7163.MCT-14-0710. Epub 2015 Jan 7.
3
Ribosomopathies: mechanisms of disease.核糖体病：疾病机制
Clin Med Insights Blood Disord. 2014 Aug 14;7:7-16. doi: 10.4137/CMBD.S16952. eCollection 2014.
4
A robust pipeline for rapid production of versatile nanobody repertoires.一种用于快速生产多功能纳米抗体库的稳健管道。
Nat Methods. 2014 Dec;11(12):1253-60. doi: 10.1038/nmeth.3170. Epub 2014 Nov 2.
5
Targeting p53-MDM2-MDMX loop for cancer therapy.靶向p53-MDM2-MDMX环路用于癌症治疗。
Subcell Biochem. 2014;85:281-319. doi: 10.1007/978-94-017-9211-0_16.
6
Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis.核糖体蛋白S27样蛋白是p53的一种生理调节因子，可抑制基因组不稳定和肿瘤发生。
Elife. 2014 Aug 21;3:e02236. doi: 10.7554/eLife.02236.
7
Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage.Mdm2 E3 连接酶功能对 p53 的调节在胚胎发生和发育中是可有可无的，但在应对 DNA 损伤时却是必不可少的。
Cancer Cell. 2014 Aug 11;26(2):235-47. doi: 10.1016/j.ccr.2014.06.006.
8
Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.与耐nutlin的Mdm2结合的订书肽拮抗剂的结构。
PLoS One. 2014 Aug 12;9(8):e104914. doi: 10.1371/journal.pone.0104914. eCollection 2014.
9
Autoantibodies response to MDM2 and p53 in the immunodiagnosis of esophageal squamous cell carcinoma.自身抗体对MDM2和p53的反应在食管鳞状细胞癌免疫诊断中的作用
Scand J Immunol. 2014 Nov;80(5):362-8. doi: 10.1111/sji.12202.
10
Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma.抗鼠双微体 2 蛋白抗体在肝细胞癌免疫诊断中的作用。
J Immunol Res. 2014;2014:906532. doi: 10.1155/2014/906532. Epub 2014 May 14.
Zotero 插件